Reports

Potential cost savings from use of biosimilars in the UK

Home/Reports | Posted 14/10/2016

A new report into the use of biological therapies to treat inflammatory bowel disease (IBD) has found that biosimilars are safe and effective for patients and if adopted can halve the cost of treatment in the UK.

Naming and interchangeability for biosimilars in Japan

Home/Reports | Posted 07/10/2016

At the 14th Annual Biosimilars Group Conference, Dr Daisaku Sato, Director, Office of Cellular and Tissue-based Products at the Pharmaceutical and Medical Devices Agency (PMDA), discussed naming rules and interchangeability for biosimilars in Japan [1].

Reference products and toxicity studies for biosimilars in Japan

Home/Reports | Posted 30/09/2016

In his presentation, at the 14th Annual Biosimilars Group Conference, Dr Daisaku Sato, Director, Office of Cellular and Tissue-based Products at the Pharmaceutical and Medical Devices Agency (PMDA), discussed what reference products are acceptable and whether repeat-dose toxicity studies are required for marketing applications for biosimilars in Japan [1].

Regulation of biosimilars in Japan

Home/Reports | Posted 23/09/2016

Biosimilar regulations, based on the European Union’s existing processes, were issued by Japan’s regulatory body for the approval of medicines, the Ministry for Health, Labour and Welfare (MHLW), in March 2009 [1]. The MHLW’s regulatory agency, the Pharmaceuticals and Medical Devices Agency (PMDA), provides consultations concerning the clinical trials of new drugs and medical devices and handles biotechnology medicines, including biosimilars.

Saving money and building trust in biosimilars

Home/Reports | Posted 05/08/2016

The increasing cost of medicines was highlighted at the Biosimilar Medicines Group (formerly EBG) satellite symposium at the European Association of Hospital Pharmacists 2016 conference [1].

Global generics market expected to grow

Home/Reports | Posted 01/07/2016

A report on the global generics market forecasts that the market will grow at a compound annual growth rate (CAGR) of 10.53% during the period 2016–2020.

Half of doctors not convinced about biosimilars

Home/Reports | Posted 24/06/2016

A survey of doctors carried out by SERMO, a global social media network, has found that half of doctors do not feel that they have enough educational information to prescribe biosimilars to their patients.

How are biosimilars important for patients?

Home/Reports | Posted 10/06/2016

In its new Biosimilars Handbook, industry association Medicines for Europe (previously the European Generic medicines Association) describes how biosimilars are important for different groups.

Medicines for Europe launches Biosimilars Handbook

Home/Reports | Posted 03/06/2016

In February 2016, Medicines for Europe (previously the European Generic medicines Association) released the Biosimilars Handbook.

South Korean pharma market to reach US$20 billion by 2020

Home/Reports | Posted 27/05/2016

The pharmaceutical market in South Korea is on the increase and is expected to reach more than US$20 billion by 2020.